Company intelligence / Profile preview

OXO Chemie AG

Wanzleben, Sachsen-Anhalt, Germanyoxots.com ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

The company has developed WF10 (Immunokine®), which is approved in Thailand for diabetic foot ulcers since 2015, and Oxovasin® (Oxoferin®), approved in Germany since 1994 for topical treatment of difficult-to-heal wounds. Clinical trials showed WF10 diminished toxic effects of hemolysis, improved microcirculation and glucose consumption in affected tissues, and prevented below knee amputation[4].

Therapeutic areas: CardiovascularImmunologyEndocrinologyDermatologyOncologyInfectious Diseases
Modalities: Small molecules (chlorite-based drugs)
Industry: Biotech

Drug pipeline

2 assets

Oxovasin

Commercial

Indications: Difficult to heal wounds

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on OXO Chemie AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXO Chemie AG.

Explore the full profile